Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal

Clicks: 245
ID: 269080
2008
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Macrolide resistance among Streptococcus pyogenes (group A streptococci) in Portugal was stable during 1998-2003, but a rapid inversion in the dominant phenotypes was noted in the same period, with a sharp decrease in the proportion of isolates presenting the MLS(B) phenotype and a concomitant incre ā€¦
Reference Key
c2008clinicaldecrease Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Silva-Costa C;Pinto FR;Ramirez M;Melo-Cristino J; ;;
Journal clinical microbiology and infection : the official publication of the european society of clinical microbiology and infectious diseases
Year 2008
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/19046174
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE gel humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult DNA Sequence Analysis Genotype drug resistance bacterial* bacterial typing techniques microbial sensitivity tests anti-bacterial agents / pharmacology* streptococcus pyogenes / isolation & purification serotyping electrophoresis pulsed-field macrolides / pharmacology* streptococcus pyogenes / drug effects* bacterial / genetics streptococcal infections / microbiology* streptococcus pyogenes / classification* cluster analysis portugal dna fingerprinting streptococcus pyogenes / genetics investigators=[] affs=[]) pmid:19046174 doi:10.1111/j.1469-0691.2008.02104.x c silva-costa f r pinto collabauthor(name='portuguese surveillance group for the study of respiratory pathogens' lincosamides / pharmacology streptogramin b / pharmacology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.